New NICE Approval

posted in: News | 0

BTOG wishes to inform members of a new NICE approval that has been published today. NICE has now reappraised dabrafenib-trametinib for BRAF V600E mutant advanced NSCLC and given a positive recommendation for the submitted indication: 1st line BRAF V600E advanced … Read More

BTOG 2023 poster prize winners

posted in: News | 0

Congratulations to all of the poster winners at BTOG 2023. The full list of the four 1st prize winners and the ten runners up can be downloaded here.

NICE publishes quality standard on tobacco

posted in: News | 0

NICE has published the Tobacco: Treating Dependence quality standard (QS207). BTOG endorses this hugely helpful quality standard which covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to … Read More

BTOG welcomes new steering committee member

posted in: News | 0

BTOG is delighted to welcome Julia McAdam to the steering committee. Julia, who is Lead Lung Cancer Clinical Nurse Specialist at Shrewsbury and Telford Hospital NHS Trust, joins as a nurse representative, replacing Karen Clayton who has stepped down from … Read More

BTOG welcomes new steering committee member

posted in: News | 0

BTOG is delighted to welcome Paula Shepherd to the steering committee. Paula is currently a lung cancer clinical nurse specialist at Liverpool University Hospital Foundation Trust. She qualified as an RGN in 2001 and her main experience has been gained … Read More

National Lung Cancer Audit Annual Report published

posted in: News | 0

The National Lung Cancer Audit (NLCA) has published its latest annual report. Utilising data provided by Public Health England (PHE), Rapid Cancer Registration Dataset (RCRD) for England, the Welsh Cancer Network and lung cancer teams in Guernsey, the report provides … Read More

Latest News for BTOG Trainees

posted in: News | 0

Trainee Journal Clubs Wednesday 27th April 2022, 17:30-18:30 BSTThis session focuses on SCLC. We will be discussing the following paper: Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from … Read More

1 2 3 4 6